SMC
SANA icon

Smith, Moore & Co’s Sana Biotechnology SANA Stock Holding History

Smith, Moore & Co’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,250
Closed -$39.9K – 555
2025
Q3 		$39.9K Sell
11,250
-11,250
-50% -$40.7K ﹤0.01% 523
2025
Q2 		$61.4K Hold
22,500
– – 0.01% 507
2025
Q1 		$37.8K Buy
22,500
+12,500
+125% +$34.9K ﹤0.01% 479
2024
Q4 		$16.3K Buy
+10,000
New +$29.8K ﹤0.01% 481

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Smith, Moore & Co's SANA Position: Q4 2025 in Review

Smith, Moore & Co sold out of Sana Biotechnology (SANA) in Q4 2025, closing a stake of 11,250 shares — an estimated $39.9K sold.

Smith, Moore & Co first reported a position in SANA in Q4 2024 and held it in 4 quarters. The position peaked at $61.4K in Q2 2025. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

  • Smith, Moore & Co reported no remaining Sana Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Smith, Moore & Co sold 11,250 Sana Biotechnology shares in Q4 2025, an estimated $39.9K.
  • Smith, Moore & Co first reported a position in Sana Biotechnology in Q4 2024 and held it in 4 quarters.
  • Smith, Moore & Co's Sana Biotechnology position peaked at $61.4K in Q2 2025.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Smith, Moore & Co's 13F filing for Q4 2025, filed 23 Jan 2026.